DiaSorin (OTCMKTS:DSRLF) Shares Gap Down - Here's What Happened

Key Points

• DiaSorin stock gapped down, opening at $71.57 after a $81.65 close (about a 12.3% drop) with only 100 shares traded at the open.
• Analysts are mixed—two Buy and two Hold ratings leave the consensus at a “Moderate Buy”; BNP Paribas Exane upgraded to neutral while Deutsche Bank reiterated a hold.
• The stock is trading below its key technicals, with the 50‑day moving average at $82.24 and the 200‑day at $83.22, signaling recent weakness.

Shares of DiaSorin S.p.A. (OTCMKTS:DSRLF - Get Free Report) gapped down before the market opened on Friday . The stock had previously closed at $81.65, but opened at $71.57. DiaSorin shares last traded at $71.57, with a volume of 100 shares.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on DSRLF shares. BNP Paribas Exane upgraded shares of DiaSorin to a "neutral" rating in a research report on Wednesday, January 28th. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of DiaSorin in a research note on Tuesday, February 10th. Two research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy".

DiaSorin Stock Performance

The business's 50-day moving average is $82.24 and its two-hundred day moving average is $83.22.

About DiaSorin

DiaSorin S.p.A. is an Italy‐based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company's shares trade on the Milan Stock Exchange and are available in the United States as over‐the‐counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin's business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.